TSE:2181
TSE:2181Professional Services

A Look at Persol Holdings (TSE:2181) Valuation Following Raised Dividend Guidance

Persol HoldingsLtd (TSE:2181) just raised its interim dividend guidance for the fiscal year ending March 2026, planning to pay JPY 5.50 per share instead of last year’s JPY 4.50. The scheduled payment date is December 10, 2025. See our latest analysis for Persol HoldingsLtd. Persol HoldingsLtd’s updated dividend outlook has clearly boosted sentiment, with a 10.2% share price return over the past month and a robust 22.4% gain year-to-date. While momentum is building in the short term, the...
TSE:4063
TSE:4063Chemicals

How a GaN Substrate Breakthrough Could Shape Shin-Etsu Chemical’s (TSE:4063) Role in Advanced Electronics

IMEC announced that Shin-Etsu Chemical's 300-mm QST substrate, developed in partnership with QROMIS, enabled a record-breaking voltage resistance in GaN power device evaluations, surpassing 800V and addressing key scalability challenges. This advance could accelerate the mass adoption of large-diameter GaN devices in fast-growing areas like AI data centers, electric vehicles, and industrial power systems. We'll examine how Shin-Etsu Chemical's breakthrough in large-diameter GaN substrate...
TSE:4183
TSE:4183Chemicals

A Look at Mitsui Chemicals (TSE:4183) Valuation After Cutting Guidance on Lower Selling Prices and Restructuring

Mitsui Chemicals (TSE:4183) just updated its outlook for the full year, lowering its operating income forecast and indicating that sales revenue will fall short of earlier estimates. The company attributes this shift mainly to declining selling prices and the impact of business restructuring. See our latest analysis for Mitsui Chemicals. While Mitsui Chemicals’ updated outlook weighed on sentiment, the company’s recent stock split and steady dividend helped steady the mood. The share price...
TSE:4528
TSE:4528Pharmaceuticals

How Investors Are Reacting To Ono Pharmaceutical (TSE:4528) Winning Japanese Approval for New Braftovi Cancer Therapy

Ono Pharmaceutical recently received supplemental approval in Japan for Braftovi (encorafenib) capsule in combination with cetuximab and chemotherapy for treating unresectable, advanced, or recurrent colorectal cancer with BRAF mutation, following positive Phase III trial results. This milestone reflects Ono's ongoing progress in advancing new cancer therapies, supported by rigorous global clinical study data and regulatory recognition. We'll explore how regulatory progress in oncology,...
TSE:8050
TSE:8050Luxury

A Look at Seiko Group (TSE:8050) Valuation After Dividend Hike and New Earnings Outlook

Seiko Group (TSE:8050) just announced higher dividends for both the quarter and the full year, as well as updated earnings guidance for fiscal 2026. This signals stronger confidence from management in future performance. See our latest analysis for Seiko Group. Seiko Group’s steady confidence has clearly resonated with investors, as the share price has climbed 41.3% year-to-date and the one-year total shareholder return stands at a robust 67.8%. The company’s multi-year track record is even...